Xgeva (Denosumab) is a cancer treatment that is used to help prevent bone fractures and other skeletal conditions that can occur in patients who have advanced types of cancer, such as breast or prostate cancer, that have spread to the bones.

Approved by the FDA, Xgeva is a targeted therapy that is used to help reduce bone complication risks and possible bone related pain that can be caused from some cancers that have an advanced stage.

Targeted cancer therapies are relatively newer cancer treatments where drugs are used to locate, or “target”, particular cancer cells and then destroy these cells, while seeking to minimize any damage to the patient’s normal, healthy cells.

Xgeva has shown benefits for helping prevent bone injuries and other skeletal complications, as well as pain, in certain cancers where the tumors have originated within particular areas of the body and then metastasize, or spread, to the bones.

When cancer cells move from from the primary tumor, the part of the body where the cancer originated, via the bloodstream, or through lymph vessels, these cells can reach other tissues within the body, such as the bones, which are a common location for these cancer cells. The tumors that occur from these cells settling within the bones are referred to as a bone metastasis.

Just about any form of cancer can spread to the bones, but there are certain cancers that are more likely to cause bone metastasis. These include the following types:

We’ve created a new page about the Xgeva cancer treatment to help provide more details on how this relatively new treatment works, including what types of side effects may result from this treatment.

More Cancer Information
Learn more about Targeted Therapy Cancer Treatment.

Find more information on other New Cancer Treatments.

Read more about how Xgeva treats bone metastases and what types of side effects it may cause.